Displaying 1 - 2 of 2
| Active Ingredient | ATAZANAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | HIV-1 infection in treatment -naïve and treatment-experienced adults and pediatric patients 6 years of age or older. |
| Caution | Rash, abdominal pain, diarrhoea, nausea, unconjugated hyper- bilirubinemia, headache, lactic acidosis. |
| Dose Range | Adult: Atazanavir 300mg/ ritonavir 100mg once daily with food. |
| Drug Interactions | |
| Pregnancy | Theoretical risk of hyperbilirubinaemia in neonate if used at term. |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ATAZANAVIR | RITONAVIR |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV-1 infection in treatment -naïve and treatment-experienced adults and pediatric patients 6 years of age or older. |
| Caution | Rash, abdominal pain, diarrhoea, nausea, unconjugated hyper- bilirubinemia, headache, lactic acidosis. |
| Dose Range | Adult: Atazanavir 300mg/ ritonavir 100mg once daily with food. |
| Drug Interactions | |
| Pregnancy | Ritonavir-Although the limited human data do not allow a better assessment of th More ... |
| Breast Feeding | Ritonavir-No reports describing the use of ritonavir during lactation have been More ... |